GSK offers glimpse at positive Phase 3 antibiotic data for urogenital gonorrhea
Two months after its urogenital gonorrhea antibiotic hit the primary endpoint in a registrational trial, GSK is providing a closer look at results as it gears up for regulatory filings in 2025. The Phase 3 EAGLE-1 trial compared GSK’s antibiotic with standard-of-care ceftriaxone plus azithromycin in 600 people with uncomplicated